



IAP4 Rec'd PCT/PTO 30 NOV 2005  
Attorney/Docket No. 36689.250  
Customer No. 000027683

PCT-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Barry J. Byrne, et al.

Appl. No. 10/519812

Filed: December 28, 2004

For: rAAV COMPOSITIONS AND METHODS FOR DELIVERY OF HUMAN FACTOR VII  
POLYPEPTIDES AND TREATMENT OF HEMOPHILIA A

§ Attorney Docket No.: 4300.014300 (36689.250)

§

§

§

Group Art Unit: Unknown

§

§

Examiner: Unknown

§

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 C.F.R. §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed information are also enclosed. The undersigned first became aware of the cited patents by their inclusion in an International Search Report issued by the ISA/US on November 14, 2005, the PCT counterpart of the present application. A copy of the search report is enclosed.

Pursuant to the amendment to 37 CFR 1.98 (a)(2)(i), as stated in an OG Notice dated October 12, 2004, copies of the U.S. patent documents listed on the enclosed modified Form PTO-1449 are not attached.

This Information Disclosure Statement is being filed within three months of the United States filing date or before the mailing date of a first Office Action on the merits. No certification or fee is required (37 CFR §1.97(b)). However, the Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account 08-1394.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

Mark D. Moore, Ph.D., Agent for Applicants  
Registration No. 42,903

Date: November 28, 2005  
HAYNES AND BOONE, LLP  
901 Main Street, Suite 3100  
Dallas, Texas 75202-3789  
Telephone: 713-547-2040  
Facsimile: 214-200-0853  
File: 36689.250  
H-582276\_1.DOC

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 28, 2005

Printed Name

Signature

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/519812
				Filing Date	12/28/2004
				Applicant(s)	Barry J. Byrne, et al.
				Art Unit	Unknown
				Examiner Name	Unknown
SHEET	1	OF	1	Attorney Docket Number	4300.014300 (36689.250)

U. S. PATENT DOCUMENTS				
Examiner's Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		6132729	10-17-2000	Thorpe, et al.
		US 2003/0228282 A1	12-11-2003	Gao, et al.
		US 2003/0013189 A1	01-16-2003	Wilson, et al.

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N

NON-PATENT LITERATURE DOCUMENTS		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume- issue number(s), publisher, city/country where published
		MARGARITIS, et al., "Long-term expression of activated FVII in vivo following AAV-mediated liver gene transfer: Implications for treatment with continuous infusion of recombinant activated FVII. Blood," November 2001, Vol. 98, No. 11, Part 1, page 696a, abstract 2908.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.